Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Up 21.0% in January

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 65,700 shares, a growth of 21.0% from the January 15th total of 54,300 shares. Currently, 4.8% of the company’s shares are short sold. Based on an average trading volume of 26,500 shares, the days-to-cover ratio is presently 2.5 days.

Alaunos Therapeutics Stock Performance

Alaunos Therapeutics stock remained flat at $1.62 during midday trading on Friday. The company had a trading volume of 5,660 shares, compared to its average volume of 20,596. Alaunos Therapeutics has a 52-week low of $1.50 and a 52-week high of $26.00. The firm has a fifty day moving average price of $1.83 and a 200-day moving average price of $2.29.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.